Reading view
Do we need AI guardians to protect us from health information overload?
npj Digital Medicine, Published online: 27 October 2025; doi:10.1038/s41746-025-02093-0
The rise of digital health technologies has provided individuals with unprecedented access to biometric data and health insights. However, excess monitoring may contribute to fatigue, anxiety, and information overload, sometimes reducing engagement and worsening outcomes. This article explores how artificial intelligence-enabled assistants might help address this challenge by filtering, contextualizing, and personalizing health information, potentially supporting informed self-management while mitigating some unintended harms of digital health technologies.Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers
Oncogene, Published online: 01 March 2025; doi:10.1038/s41388-025-03322-2
Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancersTumor microenvironment and drug resistance in lung adenocarcinoma: molecular mechanisms, prognostic implications, and therapeutic strategies
Discov Oncol. 2025 Feb 25;16(1):238. doi: 10.1007/s12672-025-01981-x.
ABSTRACT
The fight against lung adenocarcinoma (LUAD) is challenged by tumor microenvironment (TME)-mediated drug resistance, which limits effective treatment. This study examines the LUAD TME and identifies four distinct subtypes through multi-omics profiling: immune-rich, immune-exhausted, stromal-dominant, and TME-desert. Each subtype has unique molecular features, tumor diversity, and links to clinical outcomes. Immune-rich subtypes respond better to immune checkpoint inhibitors, while stromal-dominant and TME-desert subtypes show resistance to treatment and poor prognosis. Molecular analysis uncovers subtype-specific mutations, chromosomal instability, and altered signaling pathways, pointing to potential therapeutic targets. In silico drug screening identifies promising treatments for resistant subtypes. These findings, validated in independent cohorts, highlight the critical role of the TME in drug resistance and treatment response, providing insights for personalized treatment strategies in LUAD.
PMID:40000527 | PMC:PMC11861463 | DOI:10.1007/s12672-025-01981-x